206 related articles for article (PubMed ID: 25384395)
1. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
Jeudy G; Dalac-Rat S; Bonniaud B; Hervieu A; Petrella T; Collet E; Vabres P
Br J Dermatol; 2015; 172(5):1454-5. PubMed ID: 25384395
[No Abstract] [Full Text] [Related]
2. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
3. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R; Lecamwasam K; Purshouse K; Reed J; Middleton MR; Fearfield L
Br J Dermatol; 2014 Apr; 170(4):997-9. PubMed ID: 24359127
[No Abstract] [Full Text] [Related]
4. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
[TBL] [Abstract][Full Text] [Related]
5. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
8. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Vanhaecke C; Deilhes F; Chanal J; Regnier-Rosencher E; Boitier F; Boulinguez S; Avril MF; Guégan S; Dupin N; Aractingi S; Meyer N; Kramkimel N
Br J Dermatol; 2017 Oct; 177(4):e94-e95. PubMed ID: 28129668
[No Abstract] [Full Text] [Related]
10. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
11. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
12. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
13. Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.
Schilling B; Sondermann W; Griewank KG; Livingstone E; Zimmer L; Hillen U; Schadendorf D
Ann Oncol; 2015 Jan; 26(1):250-251. PubMed ID: 25355721
[No Abstract] [Full Text] [Related]
14. Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Diwakar D; Choi T; Tawbi TH; Kirkwood JM
Ann Oncol; 2014 Aug; 25(8):1670-1. PubMed ID: 24890848
[No Abstract] [Full Text] [Related]
15. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma.
Rastrelli M; Pigozzo J; di Maggio A; Tosi AL; Sileni VC; Rossi CR
Melanoma Res; 2014 Aug; 24(4):413-4. PubMed ID: 24992629
[No Abstract] [Full Text] [Related]
17. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
18. Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.
Tahseen AI; Patel NB
JAAD Case Rep; 2018 Oct; 4(9):930-933. PubMed ID: 30320198
[No Abstract] [Full Text] [Related]
19. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
20. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
[Next] [New Search]